Shots:

• The P-II/III (CAPELLA) trial evaluates lenacapavir (q6mos., SC) + antiretroviral agents vs PBO in a ratio (2:1) in 36 patients with HIV. The company presented additional data of lenacapavir + F/TAF in the P-II (CALIBRATE) trial
• The 1yr. results from both trials showed that patients achieved high rates of virologic suppression & increases in CD4, 83% & 90% of patients achieved an undetectable viral load (<50 copies/mL) @52wk. while viral load reduction from baseline of 0.5 log10 copies/mL for 14 days functional monothx. period (88% vs 17%) in (CAPELLA) trial
• The therapy was well tolerated with no drug-related SAEs, The results support the development of lenacapavir with other agents for HIV-1

 Ref: Businesswire | Image: Gilead